Inhibiting NOX enzymes to treat mulitple diseases with high medical need
The EMA reflection paper on chronic liver disease and its implications for drug development in NASH
Genetics of progressive NAFLD
Poster Presentations
Development of a diet-induced disease-mimicking in vitro model of non-alcoholic steatohepatitis / fibrosis
Presentation Slides
Targeting different pathways of NASH pathogenesis using single and combination therapies
Modulation of the mitochondrial pyruvate carrier (MPC) as a treatment for NASH
Body composition in NASH clinical trials
Liver biopsy as the gold standard for diagnosis
FDA Regulatory considerations for NASH clinical trial endpoints
Imaging based technologies for NAFLD in clinical practice
GKT831: A novel PII anti-fibrotic small molecule
The EMA reflection paper on chronic liver disease and its implications for drug development in NASH
Genetics of progressive nonalcoholic fatty liver disease
Application of non-invasive tests for liver fibrosis
Discovery and validation of protein signatures for NAFLD risk and NASH status
The Poxel NASH portfolio: PXL770 and PXL065 two Differentiated Drug Candidates with Complementary Mechanisms of Action for the Treatment of NASH
Dual GLP-1 Agonists in the Treatment Metabolic & Liver Dysfunction in NASH
Multiparametric MRI for the evaluation of NAFLD
Sustained FXR agonist as optimized, best-in-class treatment for NASH
Identifying patients with risk of adverse outcomes – where should we look more closely?
The role of lysosomal acid lipase activity in NAFLD/NASH pathogenesis
NASH Trial Recruitment: The AES Solution
RNAi strategy for the treatment of NASH: focus on astrocyte elevated Gene-1 (AEG-1)
Metabolic changes and biomarkers preceding and associated with NASH
How the gut talks to the brain to impact the liver
Diabetes and NAFLD: a vicious spiral affecting both diseases
The impact of medical devices on diabetes and fatty liver disease
Resmetirom, a highly beta selective liver-directed thyroid hormone receptor beta agonist for the treatment of NASH
Endpoint Adjudication Best Practices for NASH trials
We are using cookies to give you the best experience on our site. By continuing to use our website you are agreeing to our use of cookies.AcceptRead More